The offering of 6 million shares by Apogee Therapeutics is a significant move that could lead to dilution of existing shares, potentially causing a short-term negative impact on the stock price. However, the capital raised from this offering is likely to be used for further research and development, which could enhance the company's long-term prospects. The net impact on the stock price in the short term is uncertain, hence the neutral score.